Baseline characteristics

A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma · Source last updated 2013-05-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      14

   units

   Participants

groups

1. description

   Participants received 1.3 mg per m\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.

   id

   BG000

   title

   Bortezomib

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            8.31

            value

            62.63

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age Continuous

   unit Of Measure

   Years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            8

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            6

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice